Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Achieving plasma HIV RNA below the level of detection in clinical practice

Achieving plasma HIV RNA below the level of detection in clinical practice Clinical trials have shown that highly active antiretroviral therapy (HAART) reduces plasma HIV RNA below the detection level in up to 90 per cent of patients. To assess the independent predictors that are associated with achieving undetectable plasma HIV RNA in the daily clinical practice, we carried out a retrospective study. Among 106 HIV‐infected patients treated with HAART, 63 (59 per cent) achieved undetectable plasma HIV RNA (less than 400 copies/ml) at their last visit. Adherence with HAART (greater than 80 per cent of prescribed dose) was self‐reported by 81 patients (76 per cent). Independent predictors of achieving undetectable plasma HIV RNA were: self‐reported adherence to therapy (Odds ratio (OR) 11.79, 95 per cent Confidence intervals (CI): 3.55‐33.17, p = 0.0001) and lack of previous antiretroviral therapy (OR: 3.12, 95 per cent CI: 1.09‐8.96, p = 0.03). The efficacy of antiretroviral therapy observed in the daily clinical practice was noticeably lower than that reported in clinical trials. Patient adherence with prescribed HAART and lack of previous antiretroviral therapy are important factors related to successful therapy in the real world. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png British Journal of Clinical Governance Emerald Publishing

Achieving plasma HIV RNA below the level of detection in clinical practice

Download PDF
5 pages

Loading next page...
 
/lp/emerald-publishing/achieving-plasma-hiv-rna-below-the-level-of-detection-in-clinical-T0TUE8thQS

References (20)

Publisher
Emerald Publishing
Copyright
Copyright © 2000 MCB UP Ltd. All rights reserved.
ISSN
1466-4100
DOI
10.1108/14664100010343971
Publisher site
See Article on Publisher Site

Abstract

Clinical trials have shown that highly active antiretroviral therapy (HAART) reduces plasma HIV RNA below the detection level in up to 90 per cent of patients. To assess the independent predictors that are associated with achieving undetectable plasma HIV RNA in the daily clinical practice, we carried out a retrospective study. Among 106 HIV‐infected patients treated with HAART, 63 (59 per cent) achieved undetectable plasma HIV RNA (less than 400 copies/ml) at their last visit. Adherence with HAART (greater than 80 per cent of prescribed dose) was self‐reported by 81 patients (76 per cent). Independent predictors of achieving undetectable plasma HIV RNA were: self‐reported adherence to therapy (Odds ratio (OR) 11.79, 95 per cent Confidence intervals (CI): 3.55‐33.17, p = 0.0001) and lack of previous antiretroviral therapy (OR: 3.12, 95 per cent CI: 1.09‐8.96, p = 0.03). The efficacy of antiretroviral therapy observed in the daily clinical practice was noticeably lower than that reported in clinical trials. Patient adherence with prescribed HAART and lack of previous antiretroviral therapy are important factors related to successful therapy in the real world.

Journal

British Journal of Clinical Governance – Emerald Publishing

Published: Jun 1, 2000

Keywords: AIDS; Hospitals; Clinical guidelines

There are no references for this article.